LONDON, January 9 Amarin Corporation plc(NASDAQ: AMRN) today announced the successful completion of a preclinicalproof of concept study using a novel nasal formulation of lorazepam. Thepreclinical study evaluated the extent of absorption of lorazepam after nasaladministration and the pharmacokinetics of the novel formulation. Amarin isnow working with a subsidiary of Elan Corporation, plc (NYSE: ELN) to preparethis nasal formulation for human pharmacokinetic trials.
This nasal lorazepam formulation utilizes Elan's proprietaryNanoCrystal(R) Technology and is in development for the out-patient treatmentof emergency seizures in epilepsy patients, specifically status epilepticusand acute repetitive seizures.
About Status Epilepticus and Acute Repetitive Seizures
A seizure emergency is a prolonged seizure or continuous state offrequently occurring seizures. One common type of seizure emergency is calledstatus epilepticus (SE). SE may be defined as a prolonged seizure lastinglonger than 10 minutes. SE is also defined by a series of repeated seizureswithout the return of consciousness between seizures. SE has an annualincidence estimated at approximately 150,000 cases in the United States alonewith approximately 40,000 deaths per year.
Another type of seizure emergency is acute repetitive seizures (ARS),which is a bout or cluster of seizures over a short period of time in whichthe patient regains consciousness between seizures. It is estimated that upto 400,000 people in the United States suffer from ARS.
Epilepsy is a very common disorder affecting approximately 0.5% of thepopulation and is characterized by seizures, which may vary from the briefestlapses of attention to muscle jerks to severe and prolonged convulsions. Theymay also vary in frequency, from less than one a year to several per day.
Amarin is committed to improving the lives of patients suffering fromcentral nervous system and cardiovascular diseases. Our goal is to be aleader in the research, development and commercialization of novel drugs thataddress unmet patient needs.
Amarin's CNS development pipeline includes the recently acquiredmyasthenia gravis clinical program and preclinical programs in neuromuscular,neuronal degenerative and inflammatory diseases; Miraxion for Huntington'sdisease; two programs in Parkinson's disease; one in epilepsy; and one inmemory. Amarin is initiating a series of cardiovascular preclinical andclinical programs to capitalize on the known therapeutic benefits ofessential fatty acids in cardiovascular disease. Amarin also has twoproprietary technology platforms, a lipid-based technology platform for thetargeted transport of molecules through the liver and/or to the brain, and aunique mRNA technology based on cholinergic neuromodulation.
Amarin has its primary stock market listing in the U.S. on the NASDAQCapital Market ("AMRN") and secondary listings in the U.K. and Ireland on AIM("AMRN") and IEX ("H2E"), respectively.
The information contained in this document is as of January 9, 2008.Amarin assumes no obligation to update any forward-looking statementscontained in this document as a result of new information or future events ordevelopments. This document contains forward-looking statements aboutAmarin's financial condition, results of operations, business prospects andproducts in research that involve substantial risks and uncertainties. Youcan identify these statements by the fact that they use words such as "will","anticipate", "estimate", "expect", "project", "forecast", "intend", "plan","believe" and other words and terms of similar meaning in connection with anydiscussion of future operating or financial performance or events. Among thefactors that could cause actual results to differ materially from thosedescribed or projected herein are the foll